Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase

Yohei Doi, David L. Paterson, Jennifer M. Adams-Haduch, Hanna E. Sidjabat, Alexandra O'Keefe, Andrea Endimiani, Robert A. Bonomo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Here we describe three Escherichia coli clinical isolates with reduced susceptibility to cefepime. Sequencing of the blaCMY genes revealed two novel variants (CMY-33 and -44) with two- to four-amino-acid deletions in the H-10 helix. The deletions were responsible for 12- to 24-fold increases in the MICs of cefepime.

Original languageEnglish
Pages (from-to)3159-3161
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume53
Issue number7
DOIs
Publication statusPublished - 01-07-2009
Externally publishedYes

Fingerprint

Escherichia coli
Amino Acids
Genes
cefepime

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Doi, Yohei ; Paterson, David L. ; Adams-Haduch, Jennifer M. ; Sidjabat, Hanna E. ; O'Keefe, Alexandra ; Endimiani, Andrea ; Bonomo, Robert A. / Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase. In: Antimicrobial agents and chemotherapy. 2009 ; Vol. 53, No. 7. pp. 3159-3161.
@article{cead00c8038649139c60edf06ac1882b,
title = "Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase",
abstract = "Here we describe three Escherichia coli clinical isolates with reduced susceptibility to cefepime. Sequencing of the blaCMY genes revealed two novel variants (CMY-33 and -44) with two- to four-amino-acid deletions in the H-10 helix. The deletions were responsible for 12- to 24-fold increases in the MICs of cefepime.",
author = "Yohei Doi and Paterson, {David L.} and Adams-Haduch, {Jennifer M.} and Sidjabat, {Hanna E.} and Alexandra O'Keefe and Andrea Endimiani and Bonomo, {Robert A.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1128/AAC.00133-09",
language = "English",
volume = "53",
pages = "3159--3161",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase. / Doi, Yohei; Paterson, David L.; Adams-Haduch, Jennifer M.; Sidjabat, Hanna E.; O'Keefe, Alexandra; Endimiani, Andrea; Bonomo, Robert A.

In: Antimicrobial agents and chemotherapy, Vol. 53, No. 7, 01.07.2009, p. 3159-3161.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase

AU - Doi, Yohei

AU - Paterson, David L.

AU - Adams-Haduch, Jennifer M.

AU - Sidjabat, Hanna E.

AU - O'Keefe, Alexandra

AU - Endimiani, Andrea

AU - Bonomo, Robert A.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Here we describe three Escherichia coli clinical isolates with reduced susceptibility to cefepime. Sequencing of the blaCMY genes revealed two novel variants (CMY-33 and -44) with two- to four-amino-acid deletions in the H-10 helix. The deletions were responsible for 12- to 24-fold increases in the MICs of cefepime.

AB - Here we describe three Escherichia coli clinical isolates with reduced susceptibility to cefepime. Sequencing of the blaCMY genes revealed two novel variants (CMY-33 and -44) with two- to four-amino-acid deletions in the H-10 helix. The deletions were responsible for 12- to 24-fold increases in the MICs of cefepime.

UR - http://www.scopus.com/inward/record.url?scp=67649994326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649994326&partnerID=8YFLogxK

U2 - 10.1128/AAC.00133-09

DO - 10.1128/AAC.00133-09

M3 - Article

C2 - 19414578

AN - SCOPUS:67649994326

VL - 53

SP - 3159

EP - 3161

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -